Physician profile
Schuman Tam
NPI 1184674400
$22,662.62
in general payments reported to CMS, 2019-2025
42 companies · $3,036 in 2025
The $3,036 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,901 · 2020: $3,304 · 2021: $3,173 · 2022: $3,024 · 2023: $3,134 · 2024: $3,090 · 2025: $3,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,923 · Honoraria: $175 · Education: $95.02 · Consulting Fee: $67.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,922.81 |
| Honoraria | $175.00 |
| Education | $95.02 |
| Consulting Fee | $67.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,715.63 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $4,239.97 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,837.62 | 2019-2025 | |
| Pfizer INC. | $1,283.82 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,169.29 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Genentech USA, INC. | $1,030.90 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $1,004.30 | 2020-2025 | Hyqvia, Cuvitru, Eohilia |
| Optinose US, INC. | $931.15 | 2019-2025 | |
| Csl Behring | $722.10 | 2019-2025 | Hizentra, Haegarda |
| Octapharma USA, INC. | $561.17 | 2019-2024 | Cutaquig |
| Novartis Pharmaceuticals Corporation | $560.44 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $423.60 | 2019-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $374.16 | 2019-2023 | Airduo Digihaler |
| Alk-Abello, INC | $355.62 | 2019-2025 | Grastek, Odactra |
| Greer Laboratories, INC. | $334.66 | 2019-2025 | Oralair, Palforzia |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $333.83 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Aimmune Therapeutics, INC. | $315.66 | 2021-2023 | |
| Covis Pharma Gmbh | $300.64 | 2019-2022 | |
| Kaleo, INC. | $294.18 | 2019-2022 | |
| Amgen INC. | $285.88 | 2022-2025 | Tezspire |
| Blueprint Medicines Corporation | $206.93 | 2023-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $137.37 | 2022-2025 | |
| Leo Pharma INC. | $135.81 | 2022-2025 | Adbry |
| Biocryst US Sales Co., LLC | $102.73 | 2022-2023 | Orladeyo |
| Organon LLC | $93.70 | 2025 | Vtama |
| Bio Products Laboratory USA, INC. | $91.74 | 2021-2023 | Coagadex, Gammaplex |
| Ars Pharmaceuticals Operations, INC. | $89.13 | 2025 | Neffy |
| Abbvie INC. | $87.97 | 2021-2023 | Rinvoq |
| Incyte Corporation | $77.68 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $68.69 | 2025 | Dawnzera |
| Adma Biomanufacturing LLC | $67.48 | 2025 | |
| Circassia INC. | $61.44 | 2019-2021 | |
| Galderma Laboratories, L.P. | $55.26 | 2025 | Nemluvio |
| Biocryst Pharmaceuticals, INC. | $54.48 | 2020 | |
| Pharming Healthcare, INC. | $52.33 | 2025 | Ruconest |
| Shire North American Group INC | $49.65 | 2019 | |
| Hikma Pharmaceuticals USA | $37.91 | 2021-2023 | Kloxxado |
| Invivyd INC | $32.75 | 2024 | Pemgarda |
| Paratek Pharmaceuticals, INC. | $32.32 | 2025 | Xhance |
| Arcutis Biotherapeutics, INC. | $19.37 | 2025 | Zoryve |
| Strongbridge US INC. | $17.26 | 2020 | |
| Olympus America INC. | $16.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Schuman Tam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.